Familial amyotrophic lateral sclerosis
MONDO:0005144An instance of amyotrophic lateral sclerosis that is caused by an inherited modification of the individual's genome.
Also known as: hereditary amyotrophic lateral sclerosis
39 clinical trials for this condition and its sub-types, 2 tagged with Familial amyotrophic lateral sclerosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Familial amyotrophic lateral sclerosis
-
Spinocerebellar ataxia type 2 10 trials
1 sub-type
-
Amyotrophic lateral sclerosis type 1 8 trials
-
Amyotrophic lateral sclerosis 28 0 trials
-
Amyotrophic lateral sclerosis type 3 0 trials
-
Amyotrophic lateral sclerosis type 8 0 trials
-
Amyotrophic lateral sclerosis type 9 0 trials
-
4 sub-types
-
Could a common diabetes drug help fight ALS?
Disease control OngoingThis study tests whether metformin, a widely used diabetes drug, is safe for people with a specific genetic form of ALS (C9orf72). Over 24 weeks, 41 participants will take metformin to see if it reduces toxic proteins linked to the disease. The goal is to determine if metformin c…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug tofersen under watch for ALS patients in china
Disease control OngoingThis study checks the long-term safety of tofersen (Qalsody) in 12 Chinese adults with a specific genetic form of ALS (SOD1-ALS). Participants receive 13 doses of the drug injected into the spine over about a year. The main goal is to track any side effects and how the drug moves…
Phase 4 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a common alcoholism drug help slow ALS? new trial begins
Disease control OngoingThis early-stage study tests the safety of acamprosate, a drug used for alcohol dependence, in 30 adults with ALS who have a specific mutation in the C9orf72 gene. Participants take the pill three times daily for 24 weeks and undergo regular checkups, breathing tests, and spinal …
Phase 1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Promising Gene-Targeting drug for ALS enters final trial phase
Disease control OngoingThis study tests an experimental drug called ION363 in people with a rare, inherited form of ALS caused by FUS gene mutations. The goal is to see if the drug can slow the disease and help people live longer. About 89 participants will receive the drug via spinal injection. This i…
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Custom gene silencer takes aim at a rare form of ALS
Disease control By invitation onlyThis study tests a personalized antisense oligonucleotide drug designed for a single person with ALS caused by a specific TARDBP gene mutation. The drug aims to reduce harmful TDP-43 protein and slow disease progression. The participant's clinical function, survival, and biomarke…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug aims to tackle rare brain disease
Disease control OngoingThis early-stage trial tests a single injection of ARO-ATXN2 in 36 adults with spinocerebellar ataxia type 2, a rare genetic disorder that affects movement and coordination. The main goal is to see if the drug is safe and how the body processes it. Participants are randomly assig…
Phase 1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Phase 1/2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a shot stop ALS before it starts? new trial tests tofersen in gene carriers
Disease control OngoingThis phase 3 trial tests whether the drug tofersen can delay or prevent ALS in adults who carry a SOD1 gene mutation but have no symptoms yet. About 158 participants will receive either tofersen or a placebo, and researchers will track how many develop ALS within two years. The g…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New gene therapy targets rare, aggressive ALS
Disease control OngoingThis early-stage trial tests a gene therapy called AMT-162 in 20 adults with a specific genetic form of ALS (SOD1-ALS). The treatment is given as a single injection into the spinal fluid. The main goal is to check safety and tolerability, while also looking for early signs that i…
Phase 1/2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Spit test could spot ALS early
Diagnosis OngoingThis study is testing whether a simple saliva sample can help diagnose amyotrophic lateral sclerosis (ALS). Researchers will analyze RNA in the saliva of 653 people, including ALS patients and healthy volunteers. If the test works, it could offer a faster, less invasive way to di…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Can a stimulated muscle biopsy untangle two similar nerve and muscle diseases?
Knowledge-focused OngoingResearchers are testing a muscle biopsy method that uses mild electrical stimulation to sample the junction where nerves meet muscle. The goal is to see if this technique helps distinguish between inclusion body myositis and motor neuron disease, which can look alike. The study i…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Sniffing out Parkinson's: new study uses nose, blood, and urine to catch disease early
Knowledge-focused OngoingThis study aims to find early markers of Parkinson's disease, multiple system atrophy, and Lewy body dementia by analyzing samples from the nose, blood, and urine. Researchers will compare results from 180 people with these conditions and healthy volunteers. The goal is to improv…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Smart sleeve study aims to improve movement for nerve disease patients
Knowledge-focused By invitation onlyThis study follows 1000 people with upper motor neuron disease who are about to receive the Cionic Neural Sleeve. The sleeve uses electrical stimulation to help muscles contract at the right time during movement. Researchers will track changes in health-related quality of life us…
Sponsor: Cionic, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC